Similar Efficacy in Belatacept-Converted Kidney Transplant Recipients With Steroid-Avoiding Regimen.

ABSTRACT:

Introduction

Belatacept offers a valuable alternative to calcineurin inhibitors (CNIs) for reducing toxicity in kidney transplant recipients (KTRs). No study has evaluated the efficacy and safety of late-conversion belatacept with steroid avoidance in KTRs.

Methods

This retrospective multicentric study evaluated the efficacy and safety of a belatacept-based steroid-avoiding therapy, in comparison with concomitant steroid use. The study included KTRs from 4-French transplant centers who were converted to belatacept at least 6 months posttransplantation.

Results

Overall, 512 KTRs were converted to belatacept in a median time of 38 (15.7-83.2) months after kidney transplantation (KT), including 199 patients without steroids after conversion (BelaS-). Median follow-up tim

SUBMITTER: Chavarot N 

PROVIDER: S-EPMC11993219 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature